Clinical trial • Phase III • Haematology | Other
Clinical trial in Hereditary haemochromatosis type 1
Phase III trial for Hereditary haemochromatosis type 1. 66 participants.
Overview
- Trial Therapeutic Area
- Haematology | Other
- Trial Disease
- Hereditary haemochromatosis type 1
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 05-04-2024
- First CTIS Authorization Date
- 29-07-2024
Trial design
Phase III trial across 1 site in Austria.
- Target Sample Size
- 66
Eligibility
Recruits 66 No vulnerable population selected; consent/assent handling not specified..
- Vulnerable Population
- No vulnerable population selected; consent/assent handling not specified.
Recruitment
- Planned Sample Size
- 66
- Recruitment Window Months
- 26
- Consent Approach
- Informed consent to be provided by adult participants; assent not applicable; further details not specified.
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 66
Austria
- Earliest CTIS Part Ii Submission Date
- 30-05-2024
- Latest Decision Or Authorization Date
- 29-12-2025
- Processing Time Days
- 578
- Number Of Sites
- 1
- Number Of Participants
- 66
Sites
- Site Name
- Medical University Of Graz
- Department Name
- Department of Internal Medicine
- Principal Investigator Name
- Thomas Pieber
- Principal Investigator Email
- thomas.pieber@medunigraz.at
- Contact Person Name
- Thomas Pieber
- Contact Person Email
- thomas.pieber@medunigraz.at
- Number Of Participants
- 66
Sponsor
Primary sponsor
- Full Name
- Novo Nordisk A/S
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Denmark
Related trials
Other published trials that may interest you.